RNA therapeutics: updates and future potential DOI Open Access

Caroline Zhang,

Biliang Zhang

Science China Life Sciences, Journal Year: 2022, Volume and Issue: 66(1), P. 12 - 30

Published: Sept. 8, 2022

Language: Английский

Natural killer cells in antitumour adoptive cell immunotherapy DOI Open Access
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani

et al.

Nature reviews. Cancer, Journal Year: 2022, Volume and Issue: 22(10), P. 557 - 575

Published: July 25, 2022

Language: Английский

Citations

490

CAR immune cells: design principles, resistance and the next generation DOI
Louai Labanieh, Crystal L. Mackall

Nature, Journal Year: 2023, Volume and Issue: 614(7949), P. 635 - 648

Published: Feb. 22, 2023

Language: Английский

Citations

356

Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies DOI Creative Commons
Stefan Frantz, Moritz Hundertmark, Jeanette Schulz‐Menger

et al.

European Heart Journal, Journal Year: 2022, Volume and Issue: 43(27), P. 2549 - 2561

Published: April 15, 2022

Abstract Most patients survive acute myocardial infarction (MI). Yet this encouraging development has certain drawbacks: heart failure (HF) prevalence is increasing and affected tend to have more comorbidities worsening economic strain on healthcare systems impeding effective medical management. The heart’s pathological changes in structure and/or function, termed remodelling, significantly impact patient outcomes. Risk factors like diabetes, chronic obstructive pulmonary disease, female sex, others distinctly shape disease progression the ‘road HF’. Despite availability of HF drugs that interact with general pathways involved targeted remain absent, risk stratification poor. Hence, review, we highlight pathophysiological basis, current diagnostic methods available treatments for cardiac remodelling following MI. We further aim provide a roadmap developing improved novel interventional therapies.

Language: Английский

Citations

324

The landscape of mRNA nanomedicine DOI Open Access
Xiangang Huang, Na Kong, Xingcai Zhang

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2273 - 2287

Published: Nov. 1, 2022

Language: Английский

Citations

319

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs DOI Open Access
Sean A. Dilliard, Daniel J. Siegwart

Nature Reviews Materials, Journal Year: 2023, Volume and Issue: 8(4), P. 282 - 300

Published: Jan. 19, 2023

Language: Английский

Citations

318

Unlocking the promise of mRNA therapeutics DOI Open Access
Eduarde Rohner, Ran Yang, Kylie S. Foo

et al.

Nature Biotechnology, Journal Year: 2022, Volume and Issue: 40(11), P. 1586 - 1600

Published: Nov. 1, 2022

Language: Английский

Citations

315

Therapeutic in vivo delivery of gene editing agents DOI Creative Commons
Aditya Raguram, Samagya Banskota, David R. Liu

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(15), P. 2806 - 2827

Published: July 1, 2022

In vivo gene editing therapies offer the potential to treat root causes of many genetic diseases. Realizing promise therapeutic in requires ability safely and efficiently deliver agents relevant organs tissues vivo. Here, we review current delivery technologies that have been used enable editing, including viral vectors, lipid nanoparticles, virus-like particles. Since no single modality is likely be appropriate for every possible application, compare benefits drawbacks each method highlight opportunities future improvements.

Language: Английский

Citations

301

CAR T therapy beyond cancer: the evolution of a living drug DOI
Daniel Baker, Zoltàn Arany, Joseph A. Baur

et al.

Nature, Journal Year: 2023, Volume and Issue: 619(7971), P. 707 - 715

Published: July 26, 2023

Language: Английский

Citations

255

The landscape of aging DOI Open Access
Yusheng Cai, Wei Song, Jiaming Li

et al.

Science China Life Sciences, Journal Year: 2022, Volume and Issue: 65(12), P. 2354 - 2454

Published: Sept. 2, 2022

Language: Английский

Citations

244

mRNA-based cancer therapeutics DOI
Chuang LIU,

Qiangqiang Shi,

Xiangang Huang

et al.

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(8), P. 526 - 543

Published: June 13, 2023

Language: Английский

Citations

233